Literature DB >> 10191107

Genotype-phenotype correlations in neuronal ceroid lipofuscinosis due to palmitoyl-protein thioesterase deficiency.

S L Hofmann1, A K Das, W Yi, J Y Lu, K E Wisniewski.   

Abstract

The infantile form of neuronal ceroid lipofuscinosis (NCL) has been well studied in Finland, where there is a high carrier frequency (1:70) for a single mutation in the causative gene, CLN1, or PPT. We have recently studied a group of 29 NCL subjects in the United States with palmitoyl-protein thioesterase (PPT) deficiency and described 19 different CLN1/PPT mutations in our population. In this report, we present a review of our previous findings, including a more detailed analysis of phenotype-genotype correlations, and present previously unpublished data concerning the clinical manifestations of the disorder in children of families with multiple affected members. Our studies indicate that about half of PPT-deficient patients in the United States are very similar to Finnish infants with INCL, but that a different mutation (R151X) accounts for 40% of U.S. alleles. The Finnish mutation (R122W) is rare in the United States. The other half of U.S. PPT-deficient patients develop symptoms after the age of 2 years, much later than Finnish patients. One common mutation (the "Scottish" allele, T75P) accounts for 13% of alleles and results in a juvenile-onset phenotype that is clinically indistinguishable from JNCL with CLN3 mutations. Other rare mutations were also associated with JNCL phenotypes, such as D79G and G250V. A preliminary expression study of two of these mutant enzymes supports the conclusion that juvenile-onset NCL (JNCL with GROD) is caused by missense mutations in the PPT gene that result in mutated enzymes with residual PPT enzyme activity. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10191107     DOI: 10.1006/mgme.1999.2803

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  10 in total

Review 1.  Progressive myoclonic epilepsies: review of clinical, molecular and therapeutic aspects.

Authors:  Luis Felipe Mendonça de Siqueira
Journal:  J Neurol       Date:  2010-07-01       Impact factor: 4.849

2.  Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis.

Authors:  Marie S Roberts; Shannon L Macauley; Andrew M Wong; Denis Yilmas; Sarah Hohm; Jonathan D Cooper; Mark S Sands
Journal:  J Inherit Metab Dis       Date:  2012-02-07       Impact factor: 4.982

3.  Juvenile neuronal ceroid lipofuscinosis: clinical course and genetic studies in Spanish patients.

Authors:  María-Socorro Pérez-Poyato; Montserrat Milà Recansens; Isidre Ferrer Abizanda; Raquel Montero Sánchez; Laia Rodríguez-Revenga; Victoria Cusí Sánchez; M Mar García González; Rosario Domingo Jiménez; Rafael Camino León; Ramón Velázquez Fragua; Antonio Martínez-Bermejo; Mercè Pineda Marfà
Journal:  J Inherit Metab Dis       Date:  2011-04-16       Impact factor: 4.982

4.  An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis.

Authors:  Shannon L Macauley; Andrew M S Wong; Charles Shyng; David P Augner; Joshua T Dearborn; Yewande Pearse; Marie S Roberts; Stephen C Fowler; Jonathan D Cooper; D Martin Watterson; Mark S Sands
Journal:  J Neurosci       Date:  2014-09-24       Impact factor: 6.167

5.  The role of attenuated astrocyte activation in infantile neuronal ceroid lipofuscinosis.

Authors:  Shannon L Macauley; Milos Pekny; Mark S Sands
Journal:  J Neurosci       Date:  2011-10-26       Impact factor: 6.167

6.  The crystal structure of palmitoyl protein thioesterase 1 and the molecular basis of infantile neuronal ceroid lipofuscinosis.

Authors:  J J Bellizzi; J Widom; C Kemp; J Y Lu; A K Das; S L Hofmann; J Clardy
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

Review 7.  The neuronal ceroid-lipofuscinoses (Batten disease): a new class of lysosomal storage diseases.

Authors:  M J Bennett; S L Hofmann
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

8.  Proteomic Profiling in the Brain of CLN1 Disease Model Reveals Affected Functional Modules.

Authors:  Saara Tikka; Evanthia Monogioudi; Athanasios Gotsopoulos; Rabah Soliymani; Francesco Pezzini; Enzo Scifo; Kristiina Uusi-Rauva; Jaana Tyynelä; Marc Baumann; Anu Jalanko; Alessandro Simonati; Maciej Lalowski
Journal:  Neuromolecular Med       Date:  2015-12-26       Impact factor: 3.843

Review 9.  Interactions of the proteins of neuronal ceroid lipofuscinosis: clues to function.

Authors:  Amanda L Getty; David A Pearce
Journal:  Cell Mol Life Sci       Date:  2010-08-01       Impact factor: 9.207

10.  Investigating the Endo-Lysosomal System in Major Neurocognitive Disorders Due to Alzheimer's Disease, Frontotemporal Lobar Degeneration and Lewy Body Disease: Evidence for SORL1 as a Cross-Disease Gene.

Authors:  Luisa Benussi; Antonio Longobardi; Cemile Kocoglu; Matteo Carrara; Sonia Bellini; Clarissa Ferrari; Roland Nicsanu; Claudia Saraceno; Cristian Bonvicini; Silvia Fostinelli; Roberta Zanardini; Marcella Catania; Matthieu Moisse; Philip Van Damme; Giuseppe Di Fede; Giuliano Binetti; Christine Van Broeckhoven; Julie van der Zee; Roberta Ghidoni
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.